PHI with Blackfan-Diamond anemia
How does this condition affect your private health insurance?
Blackfan-Diamond Anemia (Diamond-Blackfan Anemia, DBA) is a rare, congenital bone marrow failure syndrome characterized by a defect in erythroid progenitor cell maturation, leading to severe macrocytic anemia, typically presenting in infancy. It is a ribosomopathy, caused by mutations in ribosomal protein genes. Patients often require chronic blood transfusions and corticosteroids. While some achieve remission, many remain transfusion-dependent. Associated congenital anomalies are common, affecting about half of patients, including craniofacial, upper limb, cardiac, and urogenital defects. Long-term complications include iron overload and an increased risk of myelodysplastic syndrome and acute myeloid leukemia.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Lifelong, typically diagnosed in early infancy and requiring ongoing management.
Duration of Illness (Lifetime)
Chronic, lifelong disease unless successfully treated with hematopoietic stem cell transplantation.
Cost of Treatment (Initial)
High, including diagnostic workup, initial blood transfusions, and corticosteroid therapy, potentially tens of thousands of dollars.
Cost of Treatment (Lifetime)
Very high, potentially hundreds of thousands to millions of dollars due to chronic blood transfusions, chelation therapy for iron overload, corticosteroids, managing complications, and potential stem cell transplantation.
Mortality Rate
Moderate to high without adequate treatment; significantly improved with modern management, but complications like iron overload, infection, and malignancy still pose risks.
Risk of Secondary Damages
High, including organ damage from iron overload (heart, liver, endocrine glands), growth retardation, corticosteroid side effects, skeletal abnormalities, and increased risk of myelodysplastic syndrome and acute myeloid leukemia.
Probability of Full Recovery
Very low without successful hematopoietic stem cell transplantation; otherwise, it is a chronic, lifelong condition requiring continuous management.
Underlying Disease Risk
Significant, with approximately 50% of patients having other congenital anomalies, such as thumb defects, craniofacial abnormalities, cardiac defects, and renal malformations.